MedTrace Logo

Multiple Dose Study Of PF-05231023 In Adult Subjects Who Have Poor Lipid Control With And Without Type 2 Diabetes Mellitus

NCT01673178 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 107

Last updated 2015-02-16

Study results available
· View outcomes & findings →

Summary

This is a trial in obese subjects who have poor lipid control with and without Type 2 diabetes mellitus to study the safety, tolerability and pharmacokinetics of multiple doses of PF-05231023

Conditions

  • Diabetes Melliuts, Type 2

Interventions

OTHER

Placebo

0.9% w/v sodium chloride injection, United States Pharmacopeia (USP), once a week for 4 weeks

DRUG

25 mg PF-05231023

25 mg IV once a week for 4 weeks

DRUG

50 mg PF-05231023

50 mg IV once a week for 4 weeks

DRUG

100 mg PF-05231023

100 mg IV once a week for 4 weeks

DRUG

150 mg PF-05231023

150 mg IV once a week for 4 weeks

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-10-31
Primary Completion
2013-08-31
Completion
2013-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01673178 on ClinicalTrials.gov